Article ; Online: In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021.
Diagnostic microbiology and infectious disease
2024 Volume 109, Issue 2, Page(s) 116235
Abstract: Objectives: Ceftazidime-avibactam (CAZ-AVI) is an option for infections caused by MDR gram-negative bacilli. In this study, we aimed to analyze the in vitro antimicrobial activity of CAZ-AVI and other antimicrobial agents against gram-negative bacilli ... ...
Abstract | Objectives: Ceftazidime-avibactam (CAZ-AVI) is an option for infections caused by MDR gram-negative bacilli. In this study, we aimed to analyze the in vitro antimicrobial activity of CAZ-AVI and other antimicrobial agents against gram-negative bacilli that were collected in Colombia between 2019 and 2021 from patients with bacteremia and skin and soft-tissue infections (SSTIs). Methods: A total of 600 Enterobacterales and 259 P. aeruginosa strains were analyzed. The phenotypic resistance of isolates, particularly non-susceptibility to meropenem, multidrug-resistant (MDR) isolates, and difficult-to-treat (DTR) P. aeruginosa, was evaluated according to CLSI breakpoints. Results: Enterobacterales had the most susceptibility to CAZ-AVI (96.5 %) and tigecycline (95 %). Tigecycline and CAZ-AVI were the antimicrobial agents with the most in vitro activity against carbapenem-resistant Enterobacterales (CRE). CAZ-AVI was the antimicrobial treatment with the most activity against P. aeruginosa. Conclusions: Tigecycline and CAZ-AVI were the antimicrobial agents with the most activity against CRE and MDR Enterobacterales. For P. aeruginosa, CAZ-AVI was the antimicrobial treatment with the most in vitro activity. |
---|---|
MeSH term(s) | Humans ; Ceftazidime/pharmacology ; Soft Tissue Infections/microbiology ; Soft Tissue Infections/drug therapy ; Colombia ; Azabicyclo Compounds/pharmacology ; Anti-Bacterial Agents/pharmacology ; Microbial Sensitivity Tests ; Drug Combinations ; Bacteremia/microbiology ; Bacteremia/drug therapy ; Gram-Negative Bacteria/drug effects ; Tigecycline/pharmacology ; Pseudomonas aeruginosa/drug effects ; Drug Resistance, Multiple, Bacterial ; Gram-Negative Bacterial Infections/microbiology ; Gram-Negative Bacterial Infections/drug therapy ; Enterobacteriaceae/drug effects ; Skin Diseases, Bacterial/microbiology ; Skin Diseases, Bacterial/drug therapy |
Chemical Substances | avibactam, ceftazidime drug combination ; Ceftazidime (9M416Z9QNR) ; Azabicyclo Compounds ; Anti-Bacterial Agents ; Drug Combinations ; Tigecycline (70JE2N95KR) |
Language | English |
Publishing date | 2024-02-29 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 604920-5 |
ISSN | 1879-0070 ; 0732-8893 |
ISSN (online) | 1879-0070 |
ISSN | 0732-8893 |
DOI | 10.1016/j.diagmicrobio.2024.116235 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1845: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.